Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 318

1.

Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation.

Correa AF, Jegede O, Haas NB, Flaherty KT, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Dutcher JP, DiPaola RS, Carducci MA, Uzzo RG.

J Clin Oncol. 2019 Jun 19:JCO1900107. doi: 10.1200/JCO.19.00107. [Epub ahead of print]

PMID:
31216227
2.

Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging.

Truong M, Baack Kukreja JE, Rais-Bahrami S, Barashi NS, Wang B, Nuffer Z, Park JH, Lam K, Frye TP, Nix JW, Thomas JV, Feng C, Chapin BF, Davis JW, Hollenberg G, Oto A, Eggener SE, Joseph JV, Weinberg E, Messing EM.

Eur Urol Oncol. 2019 May;2(3):257-264. doi: 10.1016/j.euo.2018.08.008. Epub 2019 Jan 4.

PMID:
31200839
3.

Evaluation of the UroVysion™ Test to Predict Recurrence and/or Progression of Disease After BCG for Primary High Grade Non-Muscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.

Lotan Y, Inman BA, Davis LG, Kassouf W, Messing E, Daneshmand S, Canter D, Marble HT, Joseph AM, Jewell S, Boorjian SA.

J Urol. 2019 May 23:101097JU0000000000000355. doi: 10.1097/JU.0000000000000355. [Epub ahead of print]

PMID:
31120373
4.

Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.

Kim HL, Mayerson E, Lara PN, Messing E, Tangen C, Shuch BM, Vaishampayan U.

Eur Urol Focus. 2019 May 15. pii: S2405-4569(19)30143-9. doi: 10.1016/j.euf.2019.05.006. [Epub ahead of print]

PMID:
31103605
5.

Prognostic DNA Methylation Biomarkers in High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation.

Gurung PMS, Barnett AR, Wilson JS, Hudson J, Ward DG, Messing EM, Bryan RT.

Eur Urol Focus. 2019 Feb 22. pii: S2405-4569(19)30032-X. doi: 10.1016/j.euf.2019.02.012. [Epub ahead of print] Review.

PMID:
30803927
6.

SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.

Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, Heidenreich A, Messing EM, Royce TJ, Sankin AI, Schoenberg MP, Shipley WU, Villers A, Efstathiou JA, Bellmunt J, Stenzl A.

World J Urol. 2019 Jan;37(1):61-83. doi: 10.1007/s00345-018-2606-y. Epub 2019 Jan 25. Review.

PMID:
30684034
7.

Bladder cancer extracellular vesicles drive tumorigenesis by inducing the unfolded protein response in endoplasmic reticulum of nonmalignant cells.

Wu CH, Silvers CR, Messing EM, Lee YF.

J Biol Chem. 2019 Mar 1;294(9):3207-3218. doi: 10.1074/jbc.RA118.006682. Epub 2018 Dec 28.

PMID:
30593508
8.

Antibiotic prophylaxis at the time of catheter removal after radical prostatectomy: A prospective randomized clinical trial.

Berrondo C, Feng C, Kukreja JB, Messing EM, Joseph JV.

Urol Oncol. 2019 Mar;37(3):181.e7-181.e14. doi: 10.1016/j.urolonc.2018.10.029. Epub 2018 Dec 14.

PMID:
30558984
9.

Perioperative Blood Transfusions and Bladder Cancer Outcomes.

Messing EM.

Bladder Cancer. 2018 Oct 29;4(4):445-446. doi: 10.3233/BLC-189039. No abstract available.

10.

The conundrum of recurrent low-grade tumours: to treat or to observe?

Brummelhuis ISG, Witjes JA, Messing EM.

Curr Opin Urol. 2018 Nov;28(6):557-562. doi: 10.1097/MOU.0000000000000550.

PMID:
30239413
11.

Legends in Urology.

Messing EM.

Can J Urol. 2018 Aug;25(4):9367-9369. No abstract available.

12.

Financial Toxicity of Having Bladder Cancer.

Messing EM.

Bladder Cancer. 2018 Jul 30;4(3):351-352. doi: 10.3233/BLC-189035. No abstract available.

13.

Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.

Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP Jr, Mack PC, Svatek RS, Evans CP, Hafez KS, Culkin DJ, Brand TC, Karsh LI, Holzbeierlein JM, Wilson SS, Wu G, Plets M, Vogelzang NJ, Thompson IM Jr.

JAMA. 2018 May 8;319(18):1880-1888. doi: 10.1001/jama.2018.4657.

PMID:
29801011
14.

Psychological Stress and Suicide in Bladder Cancer Patients.

Messing EM.

Bladder Cancer. 2018 Apr 26;4(2):245-246. doi: 10.3233/BLC-189031. No abstract available.

15.

Historical and contemporary perspectives on cribriform morphology in prostate cancer.

Truong M, Frye T, Messing E, Miyamoto H.

Nat Rev Urol. 2018 Aug;15(8):475-482. doi: 10.1038/s41585-018-0013-1. Review.

PMID:
29713007
16.

Recruited T cells promote the bladder cancer metastasis via up-regulation of the estrogen receptor β/IL-1/c-MET signals.

Tao L, Qiu J, Slavin S, Ou Z, Liu Z, Ge J, Zuo L, Guancial EA, Messing EM, Chang C, Yeh S.

Cancer Lett. 2018 Aug 28;430:215-223. doi: 10.1016/j.canlet.2018.03.045. Epub 2018 Apr 22.

PMID:
29684419
17.

Molecular Landscape of Non-Muscle Invasive Bladder Cancer.

Messing EM.

Bladder Cancer. 2018 Jan 20;4(1):131-132. doi: 10.3233/BLC-189027. No abstract available.

18.

Characterization of urinary extracellular vesicle proteins in muscle-invasive bladder cancer.

Silvers CR, Miyamoto H, Messing EM, Netto GJ, Lee YF.

Oncotarget. 2017 Aug 8;8(53):91199-91208. doi: 10.18632/oncotarget.20043. eCollection 2017 Oct 31.

19.

Bladder Sparing Therapy for BCG Failures - I - Intravesical Immunotherapy.

Messing EM.

Bladder Cancer. 2017 Oct 27;3(4):313-314. doi: 10.3233/BLC-179023. No abstract available.

20.

Multi-institutional nomogram predicting benign prostate pathology on magnetic resonance/ultrasound fusion biopsy in men with a prior negative 12-core systematic biopsy.

Truong M, Wang B, Gordetsky JB, Nix JW, Frye TP, Messing EM, Thomas JV, Feng C, Rais-Bahrami S.

Cancer. 2018 Jan 15;124(2):278-285. doi: 10.1002/cncr.31051. Epub 2017 Oct 4.

21.

Validation of GEMCaP as a DNA Based Biomarker to Predict Prostate Cancer Recurrence after Radical Prostatectomy.

Nguyen HG, Welty C, Lindquist K, Ngo V, Gilbert E, Bengtsson H, Magi-Galluzzi C, Jean-Gilles J, Yao J, Cooperberg M, Messing E, Klein EA, Carroll PR, Paris PL.

J Urol. 2018 Mar;199(3):719-725. doi: 10.1016/j.juro.2017.09.071. Epub 2017 Sep 20.

PMID:
28941923
22.

The BCG Shortage.

Messing EM.

Bladder Cancer. 2017 Jul 27;3(3):227-228. doi: 10.3233/BLC-179018. No abstract available.

23.

The role of urinary cytology when diagnostic workup is suspicious for upper tract urothelial carcinoma but tumour biopsy is nonconfirmatory.

Horovitz D, Meng Y, Joseph JV, Feng C, Wu G, Rashid H, Messing EM.

Can Urol Assoc J. 2017 Jul;11(7):E285-E290. doi: 10.5489/cuaj.4150. Epub 2017 Jul 11.

24.

Exploratory Subgroup Analyses of Renal Function and Overall Survival in European Organization for Research and Treatment of Cancer randomized trial of Nephron-sparing Surgery Versus Radical Nephrectomy.

Scosyrev E, Messing EM, Sylvester R, Van Poppel H.

Eur Urol Focus. 2017 Dec;3(6):599-605. doi: 10.1016/j.euf.2017.02.015. Epub 2017 Apr 4.

PMID:
28753863
25.

Rate of Symptomatic Lymphocele Formation After Extraperitoneal vs Transperitoneal Robot-Assisted Radical Prostatectomy and Bilateral Pelvic Lymphadenectomy.

Horovitz D, Lu X, Feng C, Messing EM, Joseph JV.

J Endourol. 2017 Oct;31(10):1037-1043. doi: 10.1089/end.2017.0153. Epub 2017 Aug 30.

PMID:
28741376
26.

A Comprehensive Analysis of Cribriform Morphology on Magnetic Resonance Imaging/Ultrasound Fusion Biopsy Correlated with Radical Prostatectomy Specimens.

Truong M, Feng C, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP.

J Urol. 2018 Jan;199(1):106-113. doi: 10.1016/j.juro.2017.07.037. Epub 2017 Jul 18. Erratum in: J Urol. 2017 Dec 8;:.

PMID:
28728994
27.

Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.

Ristau BT, Manola J, Haas NB, Heng DYC, Messing EM, Wood CG, Kane CJ, DiPaola RS, Uzzo RG.

J Urol. 2018 Jan;199(1):53-59. doi: 10.1016/j.juro.2017.07.042. Epub 2017 Jul 18.

28.

Perineural invasion by prostate cancer on MR/US fusion targeted biopsy is associated with extraprostatic extension and early biochemical recurrence after radical prostatectomy.

Truong M, Rais-Bahrami S, Nix JW, Messing EM, Miyamoto H, Gordetsky JB.

Hum Pathol. 2017 Aug;66:206-211. doi: 10.1016/j.humpath.2017.06.017. Epub 2017 Jul 11.

PMID:
28705708
29.

Cautery artifact understages urothelial cancer at initial transurethral resection of large bladder tumours.

Truong M, Liang L, Kukreja J, O'Brien J, Jean-Gilles J, Messing E.

Can Urol Assoc J. 2017 May;11(5):E203-E206. doi: 10.5489/cuaj.4172. Epub 2017 May 9.

30.

Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m2 ) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression.

Blute ML Jr, Kucherov V, Rushmer TJ, Damodaran S, Shi F, Abel EJ, Jarrard DF, Richards KA, Messing EM, Downs TM.

BJU Int. 2017 Sep;120(3):387-393. doi: 10.1111/bju.13904. Epub 2017 Jun 23.

31.

Editorial Comment.

Messing EM.

J Urol. 2017 Feb;197(2):313. doi: 10.1016/j.juro.2016.08.134. Epub 2016 Oct 27. No abstract available.

PMID:
28346984
32.

Re: Elective Nephron Sparing Surgery Decreases Other Cause Mortality Relative to Radical Nephrectomy Only in Specific Subgroups of Patients with Renal Cell Carcinoma.

Messing EM.

Eur Urol. 2017 Jul;72(1):153-154. doi: 10.1016/j.eururo.2017.02.035. Epub 2017 Mar 11. No abstract available.

PMID:
28292548
33.

Complete Remission of Locally Advanced Penile Squamous Cell Carcinoma after Multimodality Treatment.

Meng Y, Bernie HL, Weng TH, Ling DA, Messing EM, Guancial E.

Rare Tumors. 2016 Dec 20;8(4):6651. doi: 10.4081/rt.2016.6651. eCollection 2016 Nov 17.

34.

Impact of Gleason Subtype on Prostate Cancer Detection Using Multiparametric Magnetic Resonance Imaging: Correlation with Final Histopathology.

Truong M, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP.

J Urol. 2017 Aug;198(2):316-321. doi: 10.1016/j.juro.2017.01.077. Epub 2017 Feb 3.

PMID:
28163032
35.

A More Thorough Transurethral Resection.

Messing EM.

Bladder Cancer. 2017 Jan 27;3(1):75-77. doi: 10.3233/BLC-169014. No abstract available.

36.

Extraperitoneal vs. transperitoneal robot-assisted radical prostatectomy in patients with a history of prior inguinal hernia repair with mesh.

Horovitz D, Feng C, Messing EM, Joseph JV.

J Robot Surg. 2017 Dec;11(4):447-454. doi: 10.1007/s11701-017-0678-0. Epub 2017 Jan 24.

PMID:
28120135
37.

Extraperitoneal vs Transperitoneal Robot-Assisted Radical Prostatectomy in the Setting of Prior Abdominal or Pelvic Surgery.

Horovitz D, Feng C, Messing EM, Joseph JV.

J Endourol. 2017 Apr;31(4):366-373. doi: 10.1089/end.2016.0706. Epub 2017 Mar 1.

PMID:
28073298
38.

Checkpoint Inhibitors for Advanced Bladder Cancer.

Messing EM.

Bladder Cancer. 2016 Oct 27;2(4):473-474. doi: 10.3233/BLC-169011. No abstract available.

39.

Surgical readmissions: results of integrating pre-, peri- and postsurgical care.

Noyes K, Baack-Kukreja J, Messing EM, Schoeniger L, Galka E, Pan W, Xueya C, Fleming FJ, Monson JR, Mohile SG, Francone T.

Nurs Open. 2016 May 10;3(3):168-178. eCollection 2016 Jul.

40.

Editorial Comment.

Messing EM.

Urology. 2016 Dec;98:63. doi: 10.1016/j.urology.2016.07.041. Epub 2016 Sep 29. No abstract available.

PMID:
27692685
41.

Beyond Cisplatin - I.

Messing EM.

Bladder Cancer. 2016 Jul 27;2(3):365-367. No abstract available.

42.

Editorial Comment.

Messing EM.

Urology. 2016 Aug;94:101. doi: 10.1016/j.urology.2016.03.050. Epub 2016 May 20. No abstract available.

PMID:
27215175
43.

Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.

Guancial EA, Kilari D, Xiao GQ, Abu-Farsakh SH, Baran A, Messing EM, Kim ES.

PLoS One. 2016 May 17;11(5):e0155503. doi: 10.1371/journal.pone.0155503. eCollection 2016.

44.

Quality Improvement in Cystectomy Care with Enhanced Recovery (QUICCER) study.

Baack Kukreja JE, Kiernan M, Schempp B, Siebert A, Hontar A, Nelson B, Dolan J, Noyes K, Dozier A, Ghazi A, Rashid HH, Wu G, Messing EM.

BJU Int. 2017 Jan;119(1):38-49. doi: 10.1111/bju.13521. Epub 2016 Jun 3.

45.

Targeting estrogen/estrogen receptor alpha enhances Bacillus Calmette-Guérin efficacy in bladder cancer.

Shang Z, Li Y, Hsu I, Zhang M, Tian J, Wen S, Han R, Messing EM, Chang C, Niu Y, Yeh S.

Oncotarget. 2016 May 10;7(19):27325-35. doi: 10.18632/oncotarget.8756.

46.

Identification of extracellular vesicle-borne periostin as a feature of muscle-invasive bladder cancer.

Silvers CR, Liu YR, Wu CH, Miyamoto H, Messing EM, Lee YF.

Oncotarget. 2016 Apr 26;7(17):23335-45. doi: 10.18632/oncotarget.8024.

47.

Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.

Kilari D, Iczkowski KA, Pandya C, Robin AJ, Messing EM, Guancial E, Kim ES.

Anticancer Res. 2016 Feb;36(2):495-501.

PMID:
26851002
48.

Are we doing "better"? The discrepancy between perception and practice of enhanced recovery after cystectomy principles among urologic oncologists.

Baack Kukreja JE, Messing EM, Shah JB.

Urol Oncol. 2016 Mar;34(3):120.e17-21. doi: 10.1016/j.urolonc.2015.10.002. Epub 2015 Nov 14.

PMID:
26585947
49.

Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer.

Ramirez D, Gupta A, Canter D, Harrow B, Dobbs RW, Kucherov V, Mueller E, Streeper N, Uhlman MA, Svatek RS, Messing EM, Lotan Y.

BJU Int. 2016 May;117(5):783-6. doi: 10.1111/bju.13345. Epub 2015 Oct 29.

50.

Editorial Comment.

Kukreja JB, Messing EM.

Urology. 2015 Nov;86(5):972-3. doi: 10.1016/j.urology.2015.05.043. Epub 2015 Sep 26. No abstract available.

PMID:
26414727

Supplemental Content

Loading ...
Support Center